What is the translation of " LIJEČENJE ZBOG NUSPOJAVA " in English?

• treatment due to adverse reactions

Examples of using Liječenje zbog nuspojava in Croatian and their translations into English

Nije bilo bolesnika koji su prekinuli liječenje zbog nuspojava.
There were no patients who discontinued treatment due to ADRs.

Broj pacijenata, prekinuti liječenje zbog nuspojava, bila je slična u obje skupine 1, 5.
Number of patients, stopped treatment because of adverse effects, was similar in both groups 1,5.

Bolesnika koji su primali telavancin prekinulo je liječenje zbog nuspojava.
Treatment was discontinued due to adverse reactions in 5.0% of patients who received telavancin.

Udio bolesnika koji su prekinuli liječenje zbog nuspojava bio je 7% i za bolesnike liječene lijekom Benlysta, i za one liječene placebom.
The proportion of patients who discontinued treatment due to adverse reactions was 7% for both Benlysta-treated and placebo-treated patients.

Jedanaest posto(11%) bolesnika liječenih lijekom Cyramza i 6% bolesnika koji su primali placebo prekinulo je liječenje zbog nuspojava.
Of patients treated with Cyramza and 6% of patients on placebo discontinued therapy due to adverse events.

Niti jedan bolesnik nije prekinuo liječenje zbog nuspojava povezanih s Busilvexom.
No patients were discontinued from treatment due to adverse reactions related to Busilvex.

U kliničkim ispitivanjima sa 118 djece i adolescenata(3 do 16 godina) 6% bolesnika prekinulo je liječenje zbog nuspojava.
In clinical trials of 118 children and adolescents(3 to 16 years of age), 6% discontinued therapy due to adverse reactions.

Udio bolesnika koji su prekinuli liječenje zbog nuspojava iznosio je 9% za bolesnike liječene vedolizumabom i 10% za bolesnike liječene placebom.
The proportion of patients who discontinued treatment due to adverse events was 9% for vedolizumab-treated patients and 10% for placebo-treated patients.

U kliničkim ispitivanjima, 23, 8% ispitanika koji su primali naltrekson/ bupropion i 11, 9% ispitanika koji su primali placebo, prekinulo je liječenje zbog nuspojava.
In clinical studies, 23.8% of subjects receiving naltrexone/ bupropion and 11.9% of subjects receiving placebo discontinued treatment due to an adverse event.

Udio bolesnika koji su prekinuli liječenje zbog nuspojava iznosio je 3,3% među bolesnicima liječenima abataceptom te 2,0% među bolesnicima koji su primali placebo.
The proportion of patients who discontinued treatment due to ARs was 3.3% for abatacept- treated patients and 2.0% for placebo-treated patients.

Jedan bolesnik u skupini s 12-tjednim liječenjem(0,3%) i niti jedan bolesnik u skupini s 24-tjednim liječenjem nije prekinuo liječenje zbog nuspojava.
One patient in the 12-week treatment group(0.3%) and none of the patients in the 24-week treatment group discontinued treatment due to adverse reactions.

U kontroliranim kliničkim ispitivanjima zaustaviti liječenje zbog nuspojava su bili prisiljeni 8,8% bolesnici, prinimavshih orlistat, u usporedbi sa 5,0% placebo.
In controlled clinical trials to stop treatment because of side effects have been forced 8,8% patients, prinimavshih orlistat, compared to 5,0% placebo.

Bolesnici u dobi od 60 i više godina koji su liječeni kombinacijom kapecitabina i docetaksela češće su prekidali liječenje zbog nuspojava u usporedbi s bolesnicima mlađim od 60 godina.
Patients≥ 60 years of age treated with capecitabine plus docetaxel also had more early withdrawals from treatment due to adverse reactions compared to patients< 60 years of age.

Udio ispitanika koji su trajno obustavili liječenje zbog nuspojava iznosio je 0,2%(5/2044), a u 4,8%(99/2044) ispitanika je zbog nuspojava smanjena doza ribavirina.
The proportion of subjects who permanently discontinued treatment due to adverse reactions was 0.2%(5/2,044) and 4.8%(99/2,044) of subjects had ribavirin dose reductions due to adverse reactions..

U ispitanika koji su primali lijekove Viekirax i dasabuvir bez ribavirina, nuspojave najčešće povezane s ribavirinom(npr. mučnina, nesanica, anemija) bile su manje učestale te nijedan ispitanik(0/588) nije trajno obustavio liječenje zbog nuspojava.
In subjects receiving Viekirax and dasabuvir without ribavirin, adverse events typically associated to ribavirin(e.g. nausea, insomnia, anaemia) were less frequent and no subjects(0/588) permanently discontinued treatment due to adverse reactions.

U drugom ispitivanju, bolesnici koji su primili Yervoy s dakarbazinom preživjeli su prosječno 11 mjeseci u usporedbi s 9 mjeseci u bolesnika koji su primili placebo i dakarbazin, no otprilike trećina bolesnika koja je primila Yervoy nije mogla završiti liječenje zbog nuspojava.
In the second study, patients given Yervoy with dacarbazine survived an average of 11 months, compared with 9 months in those given placebo plus dacarbazine, but about a third of the patients given Yervoy were unable to complete treatment due to side effects.

U orlistat skupini najčešće prekida liječenja zbog nuspojava iz probavnog sustava.
In the orlistat group most frequently interrupted treatment due to side effects from the gastrointestinal tract.

Stopa prekida liječenja zbog nuspojava bila je 11,4% kod primjene vareniklina, dok je za placebo iznosila 9, 7.
The treatment discontinuation rate due to adverse reactions was 11.4% for varenicline compared with 9.7% for placebo.

Tijekom 10 tjedne akutne faze liječenja nije bilo statistički značajne razlike između skupina koje su primale duloksetin odnosno placebo s obzirom na prekid liječenja zbog nuspojava.
There was no statistically significant difference in discontinuation due to adverse events between duloxetine and placebo groups during the 10 week acute treatment phase.

U kliničkim ispitivanjima koja su trajala najmanje 2 godine, 8% bolesnika koji su primali Eperzan prekinulo je aktivno liječenje zbog nuspojave, dok je isto zabilježeno u 6% bolesnika liječenih usporednim lijekovima.
In clinical trials of at least 2 years duration, 8% of subjects in the Eperzan group discontinued active treatment because of an adverse event compared with 6% in the all comparators group.